<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00312858</url>
  </required_header>
  <id_info>
    <org_study_id>V251-067</org_study_id>
    <secondary_id>2005_075</secondary_id>
    <nct_id>NCT00312858</nct_id>
  </id_info>
  <brief_title>Concomitant Use of Hepatitis A Vaccine With Measles, Mumps, Rubella and Varicella Vaccine and Pneumococcal 7-Valent Conjugate Vaccine in Healthy 12-Month-Old Children (V251-067)</brief_title>
  <official_title>An Open, Randomized, Multicenter Study of the Safety, Tolerability, &amp; Immunogenicity of VAQTA™ Given Concomitantly With PROQUAD™ and PREVNAR™ in Healthy Children 12 Months of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hepatitis A vaccine will be given either alone or together with measles, mumps, rubella, and
      varicella vaccine and pneumococcal 7-valent conjugate vaccine at the first dose and together
      with measles, mumps, rubella, and varicella [Oka/Merck] virus vaccine at the second dose.
      Immunogenicity and safety data will be collected after each dose of vaccine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vaccines: V251, Hepatitis A Vaccine, Inactivated (VAQTA™) administered with Measles, Mumps,
      Rubella and Varicella Vaccine (ProQuad™) and Pneumococcal 7-Valent Conjugate Vaccine
      (Prevnar™) will have a Duration of Treatment: 2 Doses, 6 months apart.

      Vaccine: Hepatitis A Vaccine, Inactivated (VAQTA™), administered alone will have a Duration
      of Treatment: 2 Doses, 6 months apart.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Antibody Response to Hepatitis A - Participants With a Serological Response</measure>
    <time_frame>4 weeks Postdose 2 of hepatitis A vaccine (VAQTA™)</time_frame>
    <description>Number of participants with titer ≥10 mIU/mL, i.e., seropositive for hepatitis A antibody, regardless of initial serostatus</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antibody Response to Varicella - Participants With a Serological Response</measure>
    <time_frame>6 weeks Postdose 1 of varicella-containing vaccine (ProQuad™)</time_frame>
    <description>Participants with varicella baseline antibody titer &lt;1.25 gpELISA units/mL and Postdose 1 titers ≥1.25 gpELISA units/mL (seroconversion) and ≥5 gpELISA units/mL (seroprotection)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antibody Response to Streptococcus Pneumoniae - Geometric Mean Titers</measure>
    <time_frame>6 weeks Postvaccination of pneumococcal 7-valent conjugate vaccine (Prevnar™)</time_frame>
    <description>Serum antibodies to serotype-specific pneumococcal polysaccharides were determined by enzyme-linked immunosorbent assay</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participants With 1 or More Systemic Adverse Experience</measure>
    <time_frame>6 weeks post dose 1</time_frame>
    <description>Systemic adverse experiences are unfavorable or unintended changes in the body after getting study vaccine. They are collected the first 14 days after receipt of dose 1 of hepatitis A vaccine (VAQTA™) (Days 1 to 14) within the 6 week study period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participants With 1 or More Systemic Adverse Experience</measure>
    <time_frame>4 weeks post dose 2</time_frame>
    <description>Systemic adverse experiences are unfavorable or unintended changes in the body after getting study vaccine. They are collected the first 14 days after receipt of dose 2 of hepatitis A vaccine (VAQTA™) (Days 1 to 14) within the 4 week study period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participants With 1 or More Systemic Adverse Experience.</measure>
    <time_frame>6 months</time_frame>
    <description>Systemic adverse experiences are unfavorable or unintended changes in the body after getting study vaccine. Collected the first 14 days after each of the 2 doses of hepatitis A vaccine (VAQTA™) (Days 1 to 14), given 6 months apart</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participants With 1 or More Injection-site Adverse Experience</measure>
    <time_frame>6 weeks post dose 1</time_frame>
    <description>Injection-site adverse experiences collected the first 5 days after receipt of dose 1 of hepatitis A vaccine (VAQTA™) (Days 1 to 5) within the 6 week study period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participants With 1 or More Injection-site Adverse Experience</measure>
    <time_frame>4 weeks post dose 2</time_frame>
    <description>Injection-site adverse experiences collected the first 5 days after receipt of dose 2 of hepatitis A vaccine (VAQTA™) (Days 1 to 5) within the 4 week study period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participants With 1 or More Injection-site Adverse Experience</measure>
    <time_frame>6 months</time_frame>
    <description>Injection-site adverse experiences collected the first 5 days after receipt of each dose of hepatitis A vaccine (VAQTA™) (Days 1 to 5) over the 6 months in which the 2 doses of vaccine were administered.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participants With Elevated Temperature (≥102.2F/ ≥39.0C)</measure>
    <time_frame>6 weeks post dose 1</time_frame>
    <description>Elevated temperatures measured the first 5 days after receipt of dose 1 of hepatitis A vaccine (VAQTA™) (Days 1 to 5) within the 6 week study period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participants With Elevated Temperature (≥102.2F/ ≥39.0C)</measure>
    <time_frame>4 weeks post dose 2</time_frame>
    <description>Elevated temperatures measured the first 5 days after receipt of dose 2 of hepatitis A vaccine (VAQTA™) (Days 1 to 5) within the 4 week study period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participants With Elevated Temperature (≥102.2F/ ≥39.0C)</measure>
    <time_frame>6 months</time_frame>
    <description>Elevated temperatures measured the first 5 days after receipt of each dose of hepatitis A vaccine (VAQTA™) (Days 1 to 5) over the 6 months in which the 2 doses of vaccine were administered.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participants With 1 or More Serious Vaccine-related Adverse Experience</measure>
    <time_frame>6 weeks post dose 1</time_frame>
    <description>Serious vaccine-related adverse experience causes death, persistent or significant disability, causes or prolong a hospital stay, is a cancer, an overdose, or life-threatening. They were collected during the entire study and believed due to study vaccine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participants With 1 or More Serious Vaccine-related Adverse Experience</measure>
    <time_frame>4 weeks post dose 2</time_frame>
    <description>Serious vaccine-related adverse experience causes death, persistent or significant disability, causes or prolong a hospital stay, is a cancer, an overdose, or life-threatening. They were collected during the entire study and believed due to study vaccine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participants With 1 or More Serious Vaccine-related Adverse Experience</measure>
    <time_frame>6 months</time_frame>
    <description>Serious vaccine-related adverse experience causes death, persistent or significant disability, causes or prolong a hospital stay, is a cancer, an overdose, or life-threatening. They were collected during the entire study and believed due to study vaccine</description>
  </primary_outcome>
  <other_outcome>
    <measure>Antibody Response to Hepatitis A - Geometric Mean Titer</measure>
    <time_frame>4 weeks Postdose 2 of hepatitis A vaccine (VAQTA™)</time_frame>
    <description>Geometric Mean Titer of hepatitis A antibody, regardless of initial serostatus</description>
  </other_outcome>
  <other_outcome>
    <measure>Antibody Response to Varicella - Geometric Mean Titer</measure>
    <time_frame>6 weeks Postdose 1 of varicella-containing vaccine (ProQuad™)</time_frame>
    <description>Geometric Mean Titer of varicella antibody, baseline antibody titer was &lt;1.25 gpELISA units/mL</description>
  </other_outcome>
  <other_outcome>
    <measure>Antibody Response to S. Pneumoniae Serotype 4 - Participants With a Serological Response</measure>
    <time_frame>6 weeks postvaccination of pneumococcal 7-valent conjugate vaccine (Prevnar™)</time_frame>
    <description>Number of participants with a postvaccination titer &gt;=0.2 mcg/mL for S. pneumoniae serotype 4</description>
  </other_outcome>
  <other_outcome>
    <measure>Antibody Response to S. Pneumoniae Serotype 6B - Participants With a Serological Response</measure>
    <time_frame>6 weeks postvaccination of pneumococcal 7-valent conjugate vaccine (Prevnar™)</time_frame>
    <description>Number of participants with a postvaccination titer &gt;=0.2 mcg/mL for S. pneumoniae serotype 6B</description>
  </other_outcome>
  <other_outcome>
    <measure>Antibody Response to S. Pneumoniae Serotype 9V - Participants With a Serological Response</measure>
    <time_frame>6 weeks postvaccination of pneumococcal 7-valent conjugate vaccine (Prevnar™)</time_frame>
    <description>Number of participants with a postvaccination titer &gt;=0.2 mcg/mL for S. pneumoniae serotype 9V</description>
  </other_outcome>
  <other_outcome>
    <measure>Antibody Response to S. Pneumoniae Serotype 14 - Participants With a Serological Response</measure>
    <time_frame>6 weeks postvaccination of pneumococcal 7-valent conjugate vaccine (Prevnar™)</time_frame>
    <description>Number of participants with a postvaccination titer &gt;=0.2 mcg/mL for S. pneumoniae serotype 14</description>
  </other_outcome>
  <other_outcome>
    <measure>Antibody Response to S. Pneumoniae Serotype 18C - Participants With a Serological Response</measure>
    <time_frame>6 weeks postvaccination of pneumococcal 7-valent conjugate vaccine (Prevnar™)</time_frame>
    <description>Number of participants with a postvaccination titer &gt;=0.2 mcg/mL for S. pneumoniae serotype 18C</description>
  </other_outcome>
  <other_outcome>
    <measure>Antibody Response to S. Pneumoniae Serotype 19F - Participants With a Serological Response</measure>
    <time_frame>6 weeks postvaccination of pneumococcal 7-valent conjugate vaccine (Prevnar™)</time_frame>
    <description>Number of participants with a postvaccination titer &gt;=0.2 mcg/mL for S. pneumoniae serotype 19F</description>
  </other_outcome>
  <other_outcome>
    <measure>Antibody Response to S. Pneumoniae Serotype 23F - Participants With a Serological Response</measure>
    <time_frame>6 weeks postvaccination of pneumococcal 7-valent conjugate vaccine (Prevnar™)</time_frame>
    <description>Number of participants with a postvaccination titer &gt;=0.2 mcg/mL for S. pneumoniae serotype 23F</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">653</enrollment>
  <condition>Hepatitis A Virus</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm 1: VAQTA™ 0.5 mL injection (2 doses 6 months apart), ProQuad™ 0.5 mL injection (2 doses 6 months apart), Prevnar™ 0.5 mL injection (one dose), all vaccines administered concomitantly. 28 weeks of study duration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm 2: ProQuad™ 0.5 mL injection (2 doses ~8 months apart), Prevnar™ 0.5 mL injection (one dose), both administered concomitantly, VAQTA™ 0.5 mL injection (2 doses 6 months apart) administered alone. 34 weeks of study duration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Comparator: VAQTA™ (Hepatitis A vaccine)</intervention_name>
    <description>VAQTA™ 0.5 mL injection</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Comparator: ProQuad™ (Measles, Mumps, Rubella and Varicella vaccine)</intervention_name>
    <description>ProQuad™ 0.5 mL injection</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Comparator: Prevnar™ (Pneumococcal 7-Valent Conjugate vaccine)</intervention_name>
    <description>Prevnar™ 0.5 mL injection</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  12- to 15-month-old males and females with no active liver disease

          -  A negative history of hepatitis A, measles, mumps, rubella, chickenpox, and/or zoster

        Exclusion Criteria:

          -  Males and females previously vaccinated with hepatitis A, measles, mumps, rubella,
             and/or chickenpox vaccine

          -  Any immune deficiency

          -  History of allergy to any of the vaccine components

          -  History of any seizure disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>15 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>MedWatch - FDA maintained medical product safety Information</description>
  </link>
  <link>
    <url>http://www.merck.com/product/patients_caregivers/home.html</url>
    <description>Merck: Patient &amp; Caregiver U.S. Product Web Site</description>
  </link>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 7, 2006</study_first_submitted>
  <study_first_submitted_qc>April 7, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2006</study_first_posted>
  <results_first_submitted>March 24, 2009</results_first_submitted>
  <results_first_submitted_qc>June 12, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 3, 2009</results_first_posted>
  <last_update_submitted>March 16, 2017</last_update_submitted>
  <last_update_submitted_qc>March 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis A Virus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>39 clinical sites in the United States
Date first participant visit: 14-Apr-2006
Date last participant visit: 25-Mar-2008</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm 1: VAQTA™ + ProQuad™ + Prevnar™</title>
          <description>VAQTA™ (hepatitis A vaccine) + ProQuad™ (measles, mumps, rubella, and varicella vaccine) + Prevnar™ (pneumococcal 7-valent conjugate vaccine) administered at the same time at first study visit. Second doses of VAQTA™ and ProQuad™ administered together 24 weeks later at third study visit.</description>
        </group>
        <group group_id="P2">
          <title>Arm 2: VAQTA™ Separate From ProQuad™ and Prevnar™</title>
          <description>VAQTA™ (hepatitis A vaccine) dose 1 administered separately from ProQuad™ (measles, mumps, rubella, and varicella vaccine) and Prevnar™ (pneumococcal 7-valent conjugate vaccine). A second dose of VAQTA™ administered 24 weeks after the first dose at third study visit.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="330"/>
                <participants group_id="P2" count="323"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Visit 1</title>
              <participants_list>
                <participants group_id="P1" count="330"/>
                <participants group_id="P2" count="323"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Visit 2</title>
              <participants_list>
                <participants group_id="P1" count="305"/>
                <participants group_id="P2" count="294"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Visit 3</title>
              <participants_list>
                <participants group_id="P1" count="273"/>
                <participants group_id="P2" count="261"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Visit 4</title>
              <participants_list>
                <participants group_id="P1" count="262"/>
                <participants group_id="P2" count="240"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="262"/>
                <participants group_id="P2" count="230"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
                <participants group_id="P2" count="93"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="42"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdraw by Participant</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant Moved</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm 1: VAQTA™ + ProQuad™ + Prevnar™</title>
          <description>VAQTA™ (hepatitis A vaccine) + ProQuad™ (measles, mumps, rubella, and varicella vaccine) + Prevnar™ (pneumococcal 7-valent conjugate vaccine) administered at the same time at first study visit. Second doses of VAQTA™ and ProQuad™ administered together 24 weeks later at third study visit.</description>
        </group>
        <group group_id="B2">
          <title>Arm 2: VAQTA™ Separate From ProQuad™ and Prevnar™</title>
          <description>VAQTA™ (hepatitis A vaccine) dose 1 administered separately from ProQuad™ (measles, mumps, rubella, and varicella vaccine) and Prevnar™ (pneumococcal 7-valent conjugate vaccine). A second dose of VAQTA™ administered 24 weeks after the first dose at third study visit.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="330"/>
            <count group_id="B2" value="323"/>
            <count group_id="B3" value="653"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.4" spread="0.80"/>
                    <measurement group_id="B2" value="12.5" spread="0.89"/>
                    <measurement group_id="B3" value="12.4" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="156"/>
                    <measurement group_id="B2" value="166"/>
                    <measurement group_id="B3" value="322"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="174"/>
                    <measurement group_id="B2" value="157"/>
                    <measurement group_id="B3" value="331"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Antibody Response to Hepatitis A - Participants With a Serological Response</title>
        <description>Number of participants with titer ≥10 mIU/mL, i.e., seropositive for hepatitis A antibody, regardless of initial serostatus</description>
        <time_frame>4 weeks Postdose 2 of hepatitis A vaccine (VAQTA™)</time_frame>
        <population>Per-protocol analysis set includes participants who received 2 doses of VAQTA™ (hepatitis A vaccine), had a Postdose 2 serology results, and followed the protocol procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: VAQTA™ + ProQuad™ + Prevnar™</title>
            <description>VAQTA™ (hepatitis A vaccine) + ProQuad™ (measles, mumps, rubella, and varicella vaccine) + Prevnar™ (pneumococcal 7-valent conjugate vaccine) administered at the same time at first study visit. Second doses of VAQTA™ and ProQuad™ administered together 24 weeks later at third study visit.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: VAQTA™ Separate From ProQuad™ and Prevnar™</title>
            <description>VAQTA™ (hepatitis A vaccine) dose 1 administered separately from ProQuad™ (measles, mumps, rubella, and varicella vaccine) and Prevnar™ (pneumococcal 7-valent conjugate vaccine). A second dose of VAQTA™ administered 24 weeks after the first dose at third study visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Response to Hepatitis A - Participants With a Serological Response</title>
          <description>Number of participants with titer ≥10 mIU/mL, i.e., seropositive for hepatitis A antibody, regardless of initial serostatus</description>
          <population>Per-protocol analysis set includes participants who received 2 doses of VAQTA™ (hepatitis A vaccine), had a Postdose 2 serology results, and followed the protocol procedures.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="182"/>
                <count group_id="O2" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="182"/>
                    <measurement group_id="O2" value="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of the difference (percentage points) in estimated response rates of Arm 1 – Arm 2.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Similarity (non-inferiority) based on lower bound of the 2-sided 95% CI on the risk difference of seroresponse rates excluding a decrease of 10 percentage points or more (lower bound &gt;-10.0).</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Similarity (non-inferiority) indicated that the risk difference was statistically significantly greater than the pre-specified clinically relevant difference of -10 percentage points at the 1-sided α=0.025 level.</p_value_desc>
            <method>Miettinen and Nurminen</method>
            <method_desc>For testing the non-inferiority of 2 proportions. Stratified by investigator.</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.4</ci_lower_limit>
            <ci_upper_limit>3.8</ci_upper_limit>
            <estimate_desc>Difference in estimated response rates of Arm 1 – Arm 2.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Antibody Response to Varicella - Participants With a Serological Response</title>
        <description>Participants with varicella baseline antibody titer &lt;1.25 gpELISA units/mL and Postdose 1 titers ≥1.25 gpELISA units/mL (seroconversion) and ≥5 gpELISA units/mL (seroprotection)</description>
        <time_frame>6 weeks Postdose 1 of varicella-containing vaccine (ProQuad™)</time_frame>
        <population>Per-protocol analysis set includes participants who received the initial dose of ProQuad™ (varicella-containing vaccine), had a Postdose 1 serology result, and followed the protocol procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: VAQTA™ + ProQuad™ + Prevnar™</title>
            <description>VAQTA™ (hepatitis A vaccine) + ProQuad™ (measles, mumps, rubella, and varicella vaccine) + Prevnar™ (pneumococcal 7-valent conjugate vaccine) administered at the same time at first study visit. Second doses of VAQTA™ and ProQuad™ administered together 24 weeks later at third study visit.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: VAQTA™ Separate From ProQuad™ and Prevnar™</title>
            <description>VAQTA™ (hepatitis A vaccine) dose 1 administered separately from ProQuad™ (measles, mumps, rubella, and varicella vaccine) and Prevnar™ (pneumococcal 7-valent conjugate vaccine). A second dose of VAQTA™ administered 24 weeks after the first dose at third study visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Response to Varicella - Participants With a Serological Response</title>
          <description>Participants with varicella baseline antibody titer &lt;1.25 gpELISA units/mL and Postdose 1 titers ≥1.25 gpELISA units/mL (seroconversion) and ≥5 gpELISA units/mL (seroprotection)</description>
          <population>Per-protocol analysis set includes participants who received the initial dose of ProQuad™ (varicella-containing vaccine), had a Postdose 1 serology result, and followed the protocol procedures.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of participants ≥1.25 gpELISA units/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="222"/>
                    <measurement group_id="O2" value="231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of participants ≥5 gpELISA units/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="210"/>
                    <measurement group_id="O2" value="228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of the difference (percentage points) in estimated response rates of Arm 1 – Arm 2 for participants with initial serostatus &lt;1.25 gpELISA units/mL</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Similarity (non-inferiority) based on lower bound of the 2-sided 95% CI on the risk difference seroresponse rates excluding a decrease of 10 percentage points or more (lower bound &gt;-10.0).</non_inferiority_desc>
            <p_value>0.013</p_value>
            <p_value_desc>Similarity (non-inferiority) indicated that the risk difference was statistically significantly greater than the pre-specified clinically relevant difference of -10 percentage points at the 1-sided multiplicity-adjusted α=0.025 level.</p_value_desc>
            <method>Miettinen and Nurminen</method>
            <method_desc>For testing the non-inferiority of 2 proportions. Stratified by investigator.</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-5.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-9.3</ci_lower_limit>
            <ci_upper_limit>-1.4</ci_upper_limit>
            <estimate_desc>Difference in estimated response rates of Arm 1 – Arm 2.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Antibody Response to Streptococcus Pneumoniae - Geometric Mean Titers</title>
        <description>Serum antibodies to serotype-specific pneumococcal polysaccharides were determined by enzyme-linked immunosorbent assay</description>
        <time_frame>6 weeks Postvaccination of pneumococcal 7-valent conjugate vaccine (Prevnar™)</time_frame>
        <population>Per-protocol analysis set includes participants who received Prevnar™ (pneumococcal 7-valent conjugate vaccine), had a postvaccination serology result, and followed the protocol procedures</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: VAQTA™ + ProQuad™ + Prevnar™</title>
            <description>VAQTA™ (hepatitis A vaccine) + ProQuad™ (measles, mumps, rubella, and varicella vaccine) + Prevnar™ (pneumococcal 7-valent conjugate vaccine) administered at the same time at first study visit. Second doses of VAQTA™ and ProQuad™ administered together 24 weeks later at third study visit.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: VAQTA™ Separate From ProQuad™ and Prevnar™</title>
            <description>VAQTA™ (hepatitis A vaccine) dose 1 administered separately from ProQuad™ (measles, mumps, rubella, and varicella vaccine) and Prevnar™ (pneumococcal 7-valent conjugate vaccine). A second dose of VAQTA™ administered 24 weeks after the first dose at third study visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Response to Streptococcus Pneumoniae - Geometric Mean Titers</title>
          <description>Serum antibodies to serotype-specific pneumococcal polysaccharides were determined by enzyme-linked immunosorbent assay</description>
          <population>Per-protocol analysis set includes participants who received Prevnar™ (pneumococcal 7-valent conjugate vaccine), had a postvaccination serology result, and followed the protocol procedures</population>
          <units>mcg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="330"/>
                <count group_id="O2" value="323"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 4 (n=246, 247)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" lower_limit="1.6" upper_limit="2.1"/>
                    <measurement group_id="O2" value="1.6" lower_limit="1.4" upper_limit="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B (n=246, 246)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5" lower_limit="8.3" upper_limit="11.0"/>
                    <measurement group_id="O2" value="9.6" lower_limit="8.5" upper_limit="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V (n=247, 247)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" lower_limit="3.2" upper_limit="4.2"/>
                    <measurement group_id="O2" value="4.1" lower_limit="3.7" upper_limit="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14 (n=248, 247)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7" lower_limit="6.8" upper_limit="8.8"/>
                    <measurement group_id="O2" value="7.4" lower_limit="6.5" upper_limit="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C (n=247, 247)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" lower_limit="2.6" upper_limit="3.3"/>
                    <measurement group_id="O2" value="2.6" lower_limit="2.3" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F (n=248, 248)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" lower_limit="3.5" upper_limit="4.5"/>
                    <measurement group_id="O2" value="3.8" lower_limit="3.3" upper_limit="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F (n=247, 247)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" lower_limit="4.3" upper_limit="5.6"/>
                    <measurement group_id="O2" value="4.5" lower_limit="3.9" upper_limit="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 4</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority criterion is met if the lower bound of the 95% confidence interval of the response ratio is &gt;0.5, excluding a decrease of 2-fold or more</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Response ratio (Arm 1 / Arm 2)</param_type>
            <param_value>1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
            <estimate_desc>Response ratio is based on statistical models adjusting the GMT for combined study center and prevaccination titer</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 6B</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority criterion is met if the lower bound of the 95% confidence interval of the response ratio is &gt;0.5, excluding a decrease of 2-fold or more</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Response ratio (Arm 1 / Arm 2)</param_type>
            <param_value>1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8</ci_lower_limit>
            <ci_upper_limit>1.2</ci_upper_limit>
            <estimate_desc>Response ratio is based on statistical models adjusting the GMT for combined study center and prevaccination titer</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 9V</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority criterion is met if the lower bound of the 95% confidence interval of the response ratio is &gt;0.5, excluding a decrease of 2-fold or more</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Response ratio (Arm 1 / Arm 2)</param_type>
            <param_value>0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8</ci_lower_limit>
            <ci_upper_limit>1.0</ci_upper_limit>
            <estimate_desc>Response ratio is based on statistical models adjusting the GMT for combined study center and prevaccination titer</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 14</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority criterion is met if the lower bound of the 95% confidence interval of the response ratio is &gt;0.5, excluding a decrease of 2-fold or more</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Response ratio (Arm 1 / Arm 2)</param_type>
            <param_value>1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9</ci_lower_limit>
            <ci_upper_limit>1.2</ci_upper_limit>
            <estimate_desc>Response ratio is based on statistical models adjusting the GMT for combined study center and prevaccination titer</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 18C</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority criterion is met if the lower bound of the 95% confidence interval of the response ratio is &gt;0.5, excluding a decrease of 2-fold or more</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Response ratio (Arm 1 / Arm 2)</param_type>
            <param_value>1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
            <estimate_desc>Response ratio is based on statistical models adjusting the GMT for combined study center and prevaccination titer</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 19F</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority criterion is met if the lower bound of the 95% confidence interval of the response ratio is &gt;0.5, excluding a decrease of 2-fold or more</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Response ratio (Arm 1 / Arm 2)</param_type>
            <param_value>1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9</ci_lower_limit>
            <ci_upper_limit>1.2</ci_upper_limit>
            <estimate_desc>Response ratio is based on statistical models adjusting the GMT for combined study center and prevaccination titer</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 23F</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority criterion is met if the lower bound of the 95% confidence interval of the response ratio is &gt;0.5, excluding a decrease of 2-fold or more</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Response ratio (Arm 1 / Arm 2)</param_type>
            <param_value>1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.0</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
            <estimate_desc>Response ratio is based on statistical models adjusting the GMT for combined study center and prevaccination titer</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Participants With 1 or More Systemic Adverse Experience</title>
        <description>Systemic adverse experiences are unfavorable or unintended changes in the body after getting study vaccine. They are collected the first 14 days after receipt of dose 1 of hepatitis A vaccine (VAQTA™) (Days 1 to 14) within the 6 week study period.</description>
        <time_frame>6 weeks post dose 1</time_frame>
        <population>Includes all participants who provided safety follow-up after receipt of Dose 1 of VAQTA™ (hepatitis A vaccine)</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: VAQTA™ + ProQuad™ + Prevnar™</title>
            <description>VAQTA™ (hepatitis A vaccine) + ProQuad™ (measles, mumps, rubella, and varicella vaccine) + Prevnar™ (pneumococcal 7-valent conjugate vaccine) administered at the same time at first study visit. Second doses of VAQTA™ and ProQuad™ administered together 24 weeks later at third study visit.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: VAQTA™ Separate From ProQuad™ and Prevnar™</title>
            <description>VAQTA™ (hepatitis A vaccine) dose 1 administered separately from ProQuad™ (measles, mumps, rubella, and varicella vaccine) and Prevnar™ (pneumococcal 7-valent conjugate vaccine). A second dose of VAQTA™ administered 24 weeks after the first dose at third study visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With 1 or More Systemic Adverse Experience</title>
          <description>Systemic adverse experiences are unfavorable or unintended changes in the body after getting study vaccine. They are collected the first 14 days after receipt of dose 1 of hepatitis A vaccine (VAQTA™) (Days 1 to 14) within the 6 week study period.</description>
          <population>Includes all participants who provided safety follow-up after receipt of Dose 1 of VAQTA™ (hepatitis A vaccine)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="274"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="178"/>
                    <measurement group_id="O2" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Participants With 1 or More Systemic Adverse Experience</title>
        <description>Systemic adverse experiences are unfavorable or unintended changes in the body after getting study vaccine. They are collected the first 14 days after receipt of dose 2 of hepatitis A vaccine (VAQTA™) (Days 1 to 14) within the 4 week study period.</description>
        <time_frame>4 weeks post dose 2</time_frame>
        <population>Includes all participants who provided safety follow-up after receipt of Dose 2 of VAQTA™ (hepatitis A vaccine)</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: VAQTA™ + ProQuad™ + Prevnar™</title>
            <description>VAQTA™ (hepatitis A vaccine) + ProQuad™ (measles, mumps, rubella, and varicella vaccine) + Prevnar™ (pneumococcal 7-valent conjugate vaccine) administered at the same time at first study visit. Second doses of VAQTA™ and ProQuad™ administered together 24 weeks later at third study visit.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: VAQTA™ Separate From ProQuad™ and Prevnar™</title>
            <description>VAQTA™ (hepatitis A vaccine) dose 1 administered separately from ProQuad™ (measles, mumps, rubella, and varicella vaccine) and Prevnar™ (pneumococcal 7-valent conjugate vaccine). A second dose of VAQTA™ administered 24 weeks after the first dose at third study visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With 1 or More Systemic Adverse Experience</title>
          <description>Systemic adverse experiences are unfavorable or unintended changes in the body after getting study vaccine. They are collected the first 14 days after receipt of dose 2 of hepatitis A vaccine (VAQTA™) (Days 1 to 14) within the 4 week study period.</description>
          <population>Includes all participants who provided safety follow-up after receipt of Dose 2 of VAQTA™ (hepatitis A vaccine)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="263"/>
                <count group_id="O2" value="251"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                    <measurement group_id="O2" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Participants With 1 or More Systemic Adverse Experience.</title>
        <description>Systemic adverse experiences are unfavorable or unintended changes in the body after getting study vaccine. Collected the first 14 days after each of the 2 doses of hepatitis A vaccine (VAQTA™) (Days 1 to 14), given 6 months apart</description>
        <time_frame>6 months</time_frame>
        <population>Includes all participants who provided safety follow-up after receipt of any dose of VAQTA™ (hepatitis A vaccine)</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: VAQTA™ + ProQuad™ + Prevnar™</title>
            <description>VAQTA™ (hepatitis A vaccine) + ProQuad™ (measles, mumps, rubella, and varicella vaccine) + Prevnar™ (pneumococcal 7-valent conjugate vaccine) administered at the same time at first study visit. Second doses of VAQTA™ and ProQuad™ administered together 24 weeks later at third study visit.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: VAQTA™ Separate From ProQuad™ and Prevnar™</title>
            <description>VAQTA™ (hepatitis A vaccine) dose 1 administered separately from ProQuad™ (measles, mumps, rubella, and varicella vaccine) and Prevnar™ (pneumococcal 7-valent conjugate vaccine). A second dose of VAQTA™ administered 24 weeks after the first dose at third study visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With 1 or More Systemic Adverse Experience.</title>
          <description>Systemic adverse experiences are unfavorable or unintended changes in the body after getting study vaccine. Collected the first 14 days after each of the 2 doses of hepatitis A vaccine (VAQTA™) (Days 1 to 14), given 6 months apart</description>
          <population>Includes all participants who provided safety follow-up after receipt of any dose of VAQTA™ (hepatitis A vaccine)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="330"/>
                <count group_id="O2" value="286"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="204"/>
                    <measurement group_id="O2" value="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Participants With 1 or More Injection-site Adverse Experience</title>
        <description>Injection-site adverse experiences collected the first 5 days after receipt of dose 1 of hepatitis A vaccine (VAQTA™) (Days 1 to 5) within the 6 week study period.</description>
        <time_frame>6 weeks post dose 1</time_frame>
        <population>Includes all participants who provided safety follow-up after receipt of Dose 1 of VAQTA™ (hepatitis A vaccine)</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: VAQTA™ + ProQuad™ + Prevnar™</title>
            <description>VAQTA™ (hepatitis A vaccine) + ProQuad™ (measles, mumps, rubella, and varicella vaccine) + Prevnar™ (pneumococcal 7-valent conjugate vaccine) administered at the same time at first study visit. Second doses of VAQTA™ and ProQuad™ administered together 24 weeks later at third study visit.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: VAQTA™ Separate From ProQuad™ and Prevnar™</title>
            <description>VAQTA™ (hepatitis A vaccine) dose 1 administered separately from ProQuad™ (measles, mumps, rubella, and varicella vaccine) and Prevnar™ (pneumococcal 7-valent conjugate vaccine). A second dose of VAQTA™ administered 24 weeks after the first dose at third study visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With 1 or More Injection-site Adverse Experience</title>
          <description>Injection-site adverse experiences collected the first 5 days after receipt of dose 1 of hepatitis A vaccine (VAQTA™) (Days 1 to 5) within the 6 week study period.</description>
          <population>Includes all participants who provided safety follow-up after receipt of Dose 1 of VAQTA™ (hepatitis A vaccine)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="274"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                    <measurement group_id="O2" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Participants With 1 or More Injection-site Adverse Experience</title>
        <description>Injection-site adverse experiences collected the first 5 days after receipt of dose 2 of hepatitis A vaccine (VAQTA™) (Days 1 to 5) within the 4 week study period.</description>
        <time_frame>4 weeks post dose 2</time_frame>
        <population>Includes all participants who provided safety follow-up after receipt of Dose 2 of VAQTA™ (hepatitis A vaccine)</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: VAQTA™ + ProQuad™ + Prevnar™</title>
            <description>VAQTA™ (hepatitis A vaccine) + ProQuad™ (measles, mumps, rubella, and varicella vaccine) + Prevnar™ (pneumococcal 7-valent conjugate vaccine) administered at the same time at first study visit. Second doses of VAQTA™ and ProQuad™ administered together 24 weeks later at third study visit.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: VAQTA™ Separate From ProQuad™ and Prevnar™</title>
            <description>VAQTA™ (hepatitis A vaccine) dose 1 administered separately from ProQuad™ (measles, mumps, rubella, and varicella vaccine) and Prevnar™ (pneumococcal 7-valent conjugate vaccine). A second dose of VAQTA™ administered 24 weeks after the first dose at third study visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With 1 or More Injection-site Adverse Experience</title>
          <description>Injection-site adverse experiences collected the first 5 days after receipt of dose 2 of hepatitis A vaccine (VAQTA™) (Days 1 to 5) within the 4 week study period.</description>
          <population>Includes all participants who provided safety follow-up after receipt of Dose 2 of VAQTA™ (hepatitis A vaccine)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="263"/>
                <count group_id="O2" value="251"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Participants With 1 or More Injection-site Adverse Experience</title>
        <description>Injection-site adverse experiences collected the first 5 days after receipt of each dose of hepatitis A vaccine (VAQTA™) (Days 1 to 5) over the 6 months in which the 2 doses of vaccine were administered.</description>
        <time_frame>6 months</time_frame>
        <population>Includes all participants who provided safety follow-up after receipt of any dose of VAQTA™ (hepatitis A vaccine)</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: VAQTA™ + ProQuad™ + Prevnar™</title>
            <description>VAQTA™ (hepatitis A vaccine) + ProQuad™ (measles, mumps, rubella, and varicella vaccine) + Prevnar™ (pneumococcal 7-valent conjugate vaccine) administered at the same time at first study visit. Second doses of VAQTA™ and ProQuad™ administered together 24 weeks later at third study visit.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: VAQTA™ Separate From ProQuad™ and Prevnar™</title>
            <description>VAQTA™ (hepatitis A vaccine) dose 1 administered separately from ProQuad™ (measles, mumps, rubella, and varicella vaccine) and Prevnar™ (pneumococcal 7-valent conjugate vaccine). A second dose of VAQTA™ administered 24 weeks after the first dose at third study visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With 1 or More Injection-site Adverse Experience</title>
          <description>Injection-site adverse experiences collected the first 5 days after receipt of each dose of hepatitis A vaccine (VAQTA™) (Days 1 to 5) over the 6 months in which the 2 doses of vaccine were administered.</description>
          <population>Includes all participants who provided safety follow-up after receipt of any dose of VAQTA™ (hepatitis A vaccine)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="330"/>
                <count group_id="O2" value="286"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105"/>
                    <measurement group_id="O2" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Participants With Elevated Temperature (≥102.2F/ ≥39.0C)</title>
        <description>Elevated temperatures measured the first 5 days after receipt of dose 1 of hepatitis A vaccine (VAQTA™) (Days 1 to 5) within the 6 week study period.</description>
        <time_frame>6 weeks post dose 1</time_frame>
        <population>Includes all participants who provided safety follow-up after receipt of Dose 1 of VAQTA™ (hepatitis A vaccine)</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: VAQTA™ + ProQuad™ + Prevnar™</title>
            <description>VAQTA™ (hepatitis A vaccine) + ProQuad™ (measles, mumps, rubella, and varicella vaccine) + Prevnar™ (pneumococcal 7-valent conjugate vaccine) administered at the same time at first study visit. Second doses of VAQTA™ and ProQuad™ administered together 24 weeks later at third study visit.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: VAQTA™ Separate From ProQuad™ and Prevnar™</title>
            <description>VAQTA™ (hepatitis A vaccine) dose 1 administered separately from ProQuad™ (measles, mumps, rubella, and varicella vaccine) and Prevnar™ (pneumococcal 7-valent conjugate vaccine). A second dose of VAQTA™ administered 24 weeks after the first dose at third study visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Elevated Temperature (≥102.2F/ ≥39.0C)</title>
          <description>Elevated temperatures measured the first 5 days after receipt of dose 1 of hepatitis A vaccine (VAQTA™) (Days 1 to 5) within the 6 week study period.</description>
          <population>Includes all participants who provided safety follow-up after receipt of Dose 1 of VAQTA™ (hepatitis A vaccine)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="285"/>
                <count group_id="O2" value="243"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Participants With Elevated Temperature (≥102.2F/ ≥39.0C)</title>
        <description>Elevated temperatures measured the first 5 days after receipt of dose 2 of hepatitis A vaccine (VAQTA™) (Days 1 to 5) within the 4 week study period.</description>
        <time_frame>4 weeks post dose 2</time_frame>
        <population>Includes all participants who provided safety follow-up after receipt of Dose 2 of VAQTA™ (hepatitis A vaccine)</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: VAQTA™ + ProQuad™ + Prevnar™</title>
            <description>VAQTA™ (hepatitis A vaccine) + ProQuad™ (measles, mumps, rubella, and varicella vaccine) + Prevnar™ (pneumococcal 7-valent conjugate vaccine) administered at the same time at first study visit. Second doses of VAQTA™ and ProQuad™ administered together 24 weeks later at third study visit.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: VAQTA™ Separate From ProQuad™ and Prevnar™</title>
            <description>VAQTA™ (hepatitis A vaccine) dose 1 administered separately from ProQuad™ (measles, mumps, rubella, and varicella vaccine) and Prevnar™ (pneumococcal 7-valent conjugate vaccine). A second dose of VAQTA™ administered 24 weeks after the first dose at third study visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Elevated Temperature (≥102.2F/ ≥39.0C)</title>
          <description>Elevated temperatures measured the first 5 days after receipt of dose 2 of hepatitis A vaccine (VAQTA™) (Days 1 to 5) within the 4 week study period.</description>
          <population>Includes all participants who provided safety follow-up after receipt of Dose 2 of VAQTA™ (hepatitis A vaccine)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="237"/>
                <count group_id="O2" value="221"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Participants With Elevated Temperature (≥102.2F/ ≥39.0C)</title>
        <description>Elevated temperatures measured the first 5 days after receipt of each dose of hepatitis A vaccine (VAQTA™) (Days 1 to 5) over the 6 months in which the 2 doses of vaccine were administered.</description>
        <time_frame>6 months</time_frame>
        <population>Includes all participants who provided safety follow-up after receipt of any dose of VAQTA™ (hepatitis A vaccine)</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: VAQTA™ + ProQuad™ + Prevnar™</title>
            <description>VAQTA™ (hepatitis A vaccine) + ProQuad™ (measles, mumps, rubella, and varicella vaccine) + Prevnar™ (pneumococcal 7-valent conjugate vaccine) administered at the same time at first study visit. Second doses of VAQTA™ and ProQuad™ administered together 24 weeks later at third study visit.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: VAQTA™ Separate From ProQuad™ and Prevnar™</title>
            <description>VAQTA™ (hepatitis A vaccine) dose 1 administered separately from ProQuad™ (measles, mumps, rubella, and varicella vaccine) and Prevnar™ (pneumococcal 7-valent conjugate vaccine). A second dose of VAQTA™ administered 24 weeks after the first dose at third study visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Elevated Temperature (≥102.2F/ ≥39.0C)</title>
          <description>Elevated temperatures measured the first 5 days after receipt of each dose of hepatitis A vaccine (VAQTA™) (Days 1 to 5) over the 6 months in which the 2 doses of vaccine were administered.</description>
          <population>Includes all participants who provided safety follow-up after receipt of any dose of VAQTA™ (hepatitis A vaccine)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="293"/>
                <count group_id="O2" value="257"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Participants With 1 or More Serious Vaccine-related Adverse Experience</title>
        <description>Serious vaccine-related adverse experience causes death, persistent or significant disability, causes or prolong a hospital stay, is a cancer, an overdose, or life-threatening. They were collected during the entire study and believed due to study vaccine</description>
        <time_frame>6 weeks post dose 1</time_frame>
        <population>Includes all participants who provided safety follow-up after receipt of Dose 1 of VAQTA™ (hepatitis A vaccine)</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: VAQTA™ + ProQuad™ + Prevnar™</title>
            <description>VAQTA™ (hepatitis A vaccine) + ProQuad™ (measles, mumps, rubella, and varicella vaccine) + Prevnar™ (pneumococcal 7-valent conjugate vaccine) administered at the same time at first study visit. Second doses of VAQTA™ and ProQuad™ administered together 24 weeks later at third study visit.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: VAQTA™ Separate From ProQuad™ and Prevnar™</title>
            <description>VAQTA™ (hepatitis A vaccine) dose 1 administered separately from ProQuad™ (measles, mumps, rubella, and varicella vaccine) and Prevnar™ (pneumococcal 7-valent conjugate vaccine). A second dose of VAQTA™ administered 24 weeks after the first dose at third study visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With 1 or More Serious Vaccine-related Adverse Experience</title>
          <description>Serious vaccine-related adverse experience causes death, persistent or significant disability, causes or prolong a hospital stay, is a cancer, an overdose, or life-threatening. They were collected during the entire study and believed due to study vaccine</description>
          <population>Includes all participants who provided safety follow-up after receipt of Dose 1 of VAQTA™ (hepatitis A vaccine)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="274"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Participants With 1 or More Serious Vaccine-related Adverse Experience</title>
        <description>Serious vaccine-related adverse experience causes death, persistent or significant disability, causes or prolong a hospital stay, is a cancer, an overdose, or life-threatening. They were collected during the entire study and believed due to study vaccine</description>
        <time_frame>4 weeks post dose 2</time_frame>
        <population>Includes all participants who provided safety follow-up after receipt of Dose 2 of VAQTA™ (hepatitis A vaccine)</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: VAQTA™ + ProQuad™ + Prevnar™</title>
            <description>VAQTA™ (hepatitis A vaccine) + ProQuad™ (measles, mumps, rubella, and varicella vaccine) + Prevnar™ (pneumococcal 7-valent conjugate vaccine) administered at the same time at first study visit. Second doses of VAQTA™ and ProQuad™ administered together 24 weeks later at third study visit.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: VAQTA™ Separate From ProQuad™ and Prevnar™</title>
            <description>VAQTA™ (hepatitis A vaccine) dose 1 administered separately from ProQuad™ (measles, mumps, rubella, and varicella vaccine) and Prevnar™ (pneumococcal 7-valent conjugate vaccine). A second dose of VAQTA™ administered 24 weeks after the first dose at third study visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With 1 or More Serious Vaccine-related Adverse Experience</title>
          <description>Serious vaccine-related adverse experience causes death, persistent or significant disability, causes or prolong a hospital stay, is a cancer, an overdose, or life-threatening. They were collected during the entire study and believed due to study vaccine</description>
          <population>Includes all participants who provided safety follow-up after receipt of Dose 2 of VAQTA™ (hepatitis A vaccine)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="263"/>
                <count group_id="O2" value="251"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Participants With 1 or More Serious Vaccine-related Adverse Experience</title>
        <description>Serious vaccine-related adverse experience causes death, persistent or significant disability, causes or prolong a hospital stay, is a cancer, an overdose, or life-threatening. They were collected during the entire study and believed due to study vaccine</description>
        <time_frame>6 months</time_frame>
        <population>Includes all participants who provided safety follow-up after receipt of any dose of VAQTA™ (hepatitis A vaccine)</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: VAQTA™ + ProQuad™ + Prevnar™</title>
            <description>VAQTA™ (hepatitis A vaccine) + ProQuad™ (measles, mumps, rubella, and varicella vaccine) + Prevnar™ (pneumococcal 7-valent conjugate vaccine) administered at the same time at first study visit. Second doses of VAQTA™ and ProQuad™ administered together 24 weeks later at third study visit.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: VAQTA™ Separate From ProQuad™ and Prevnar™</title>
            <description>VAQTA™ (hepatitis A vaccine) dose 1 administered separately from ProQuad™ (measles, mumps, rubella, and varicella vaccine) and Prevnar™ (pneumococcal 7-valent conjugate vaccine). A second dose of VAQTA™ administered 24 weeks after the first dose at third study visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With 1 or More Serious Vaccine-related Adverse Experience</title>
          <description>Serious vaccine-related adverse experience causes death, persistent or significant disability, causes or prolong a hospital stay, is a cancer, an overdose, or life-threatening. They were collected during the entire study and believed due to study vaccine</description>
          <population>Includes all participants who provided safety follow-up after receipt of any dose of VAQTA™ (hepatitis A vaccine)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="330"/>
                <count group_id="O2" value="286"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Antibody Response to Hepatitis A – Geometric Mean Titer</title>
        <description>Geometric Mean Titer of hepatitis A antibody, regardless of initial serostatus</description>
        <time_frame>4 weeks Postdose 2 of hepatitis A vaccine (VAQTA™)</time_frame>
        <population>Per-protocol analysis set includes participants who received 2 doses of VAQTA™ (hepatitis A vaccine), had a Postdose 2 serology results, and followed the protocol procedures</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: VAQTA™ + ProQuad™ + Prevnar™</title>
            <description>VAQTA™ (hepatitis A vaccine) + ProQuad™ (measles, mumps, rubella, and varicella vaccine) + Prevnar™ (pneumococcal 7-valent conjugate vaccine) administered at the same time at first study visit. Second doses of VAQTA™ and ProQuad™ administered together 24 weeks later at third study visit.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: VAQTA™ Separate From ProQuad™ and Prevnar™</title>
            <description>VAQTA™ (hepatitis A vaccine) dose 1 administered separately from ProQuad™ (measles, mumps, rubella, and varicella vaccine) and Prevnar™ (pneumococcal 7-valent conjugate vaccine). A second dose of VAQTA™ administered 24 weeks after the first dose at third study visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Response to Hepatitis A – Geometric Mean Titer</title>
          <description>Geometric Mean Titer of hepatitis A antibody, regardless of initial serostatus</description>
          <population>Per-protocol analysis set includes participants who received 2 doses of VAQTA™ (hepatitis A vaccine), had a Postdose 2 serology results, and followed the protocol procedures</population>
          <units>mIU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="182"/>
                <count group_id="O2" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4976.6" lower_limit="4067.6" upper_limit="6088.6"/>
                    <measurement group_id="O2" value="6123.2" lower_limit="4825.6" upper_limit="7769.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Antibody Response to Varicella - Geometric Mean Titer</title>
        <description>Geometric Mean Titer of varicella antibody, baseline antibody titer was &lt;1.25 gpELISA units/mL</description>
        <time_frame>6 weeks Postdose 1 of varicella-containing vaccine (ProQuad™)</time_frame>
        <population>Per-protocol analysis set includes participants who received the initial dose of ProQuad™ (varicella-containing vaccine), had a Postdose 1 serology result, and followed the protocol procedures</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: VAQTA™ + ProQuad™ + Prevnar™</title>
            <description>VAQTA™ (hepatitis A vaccine) + ProQuad™ (measles, mumps, rubella, and varicella vaccine) + Prevnar™ (pneumococcal 7-valent conjugate vaccine) administered at the same time at first study visit. Second doses of VAQTA™ and ProQuad™ administered together 24 weeks later at third study visit.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: VAQTA™ Separate From ProQuad™ and Prevnar™</title>
            <description>VAQTA™ (hepatitis A vaccine) dose 1 administered separately from ProQuad™ (measles, mumps, rubella, and varicella vaccine) and Prevnar™ (pneumococcal 7-valent conjugate vaccine). A second dose of VAQTA™ administered 24 weeks after the first dose at third study visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Response to Varicella - Geometric Mean Titer</title>
          <description>Geometric Mean Titer of varicella antibody, baseline antibody titer was &lt;1.25 gpELISA units/mL</description>
          <population>Per-protocol analysis set includes participants who received the initial dose of ProQuad™ (varicella-containing vaccine), had a Postdose 1 serology result, and followed the protocol procedures</population>
          <units>gpELISA units/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.6" lower_limit="13.3" upper_limit="16.1"/>
                    <measurement group_id="O2" value="16.4" lower_limit="15.1" upper_limit="17.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Antibody Response to S. Pneumoniae Serotype 4 - Participants With a Serological Response</title>
        <description>Number of participants with a postvaccination titer &gt;=0.2 mcg/mL for S. pneumoniae serotype 4</description>
        <time_frame>6 weeks postvaccination of pneumococcal 7-valent conjugate vaccine (Prevnar™)</time_frame>
        <population>Per-protocol analysis set includes participants who received Prevnar™ (pneumococcal 7-valent conjugate vaccine), had a postvaccination serology result, and followed the protocol procedures. Serotype 4 is one of 7 individual serotypes contained in Prevnar™.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: VAQTA™ + ProQuad™ + Prevnar™</title>
            <description>VAQTA™ (hepatitis A vaccine) + ProQuad™ (measles, mumps, rubella, and varicella vaccine) + Prevnar™ (pneumococcal 7-valent conjugate vaccine) administered at the same time at first study visit. Second doses of VAQTA™ and ProQuad™ administered together 24 weeks later at third study visit.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: VAQTA™ Separate From ProQuad™ and Prevnar™</title>
            <description>VAQTA™ (hepatitis A vaccine) dose 1 administered separately from ProQuad™ (measles, mumps, rubella, and varicella vaccine) and Prevnar™ (pneumococcal 7-valent conjugate vaccine). A second dose of VAQTA™ administered 24 weeks after the first dose at third study visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Response to S. Pneumoniae Serotype 4 - Participants With a Serological Response</title>
          <description>Number of participants with a postvaccination titer &gt;=0.2 mcg/mL for S. pneumoniae serotype 4</description>
          <population>Per-protocol analysis set includes participants who received Prevnar™ (pneumococcal 7-valent conjugate vaccine), had a postvaccination serology result, and followed the protocol procedures. Serotype 4 is one of 7 individual serotypes contained in Prevnar™.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="246"/>
                <count group_id="O2" value="247"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="241"/>
                    <measurement group_id="O2" value="237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Antibody Response to S. Pneumoniae Serotype 6B - Participants With a Serological Response</title>
        <description>Number of participants with a postvaccination titer &gt;=0.2 mcg/mL for S. pneumoniae serotype 6B</description>
        <time_frame>6 weeks postvaccination of pneumococcal 7-valent conjugate vaccine (Prevnar™)</time_frame>
        <population>Per-protocol analysis set includes participants who received Prevnar™ (pneumococcal 7-valent conjugate vaccine), had a postvaccination serology result, and followed the protocol procedures. Serotype 6B is one of 7 individual serotypes contained in Prevnar™.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: VAQTA™ + ProQuad™ + Prevnar™</title>
            <description>VAQTA™ (hepatitis A vaccine) + ProQuad™ (measles, mumps, rubella, and varicella vaccine) + Prevnar™ (pneumococcal 7-valent conjugate vaccine) administered at the same time at first study visit. Second doses of VAQTA™ and ProQuad™ administered together 24 weeks later at third study visit.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: VAQTA™ Separate From ProQuad™ and Prevnar™</title>
            <description>VAQTA™ (hepatitis A vaccine) dose 1 administered separately from ProQuad™ (measles, mumps, rubella, and varicella vaccine) and Prevnar™ (pneumococcal 7-valent conjugate vaccine). A second dose of VAQTA™ administered 24 weeks after the first dose at third study visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Response to S. Pneumoniae Serotype 6B - Participants With a Serological Response</title>
          <description>Number of participants with a postvaccination titer &gt;=0.2 mcg/mL for S. pneumoniae serotype 6B</description>
          <population>Per-protocol analysis set includes participants who received Prevnar™ (pneumococcal 7-valent conjugate vaccine), had a postvaccination serology result, and followed the protocol procedures. Serotype 6B is one of 7 individual serotypes contained in Prevnar™.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="246"/>
                <count group_id="O2" value="246"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="242"/>
                    <measurement group_id="O2" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Antibody Response to S. Pneumoniae Serotype 9V - Participants With a Serological Response</title>
        <description>Number of participants with a postvaccination titer &gt;=0.2 mcg/mL for S. pneumoniae serotype 9V</description>
        <time_frame>6 weeks postvaccination of pneumococcal 7-valent conjugate vaccine (Prevnar™)</time_frame>
        <population>Per-protocol analysis set includes participants who received Prevnar™ (pneumococcal 7-valent conjugate vaccine), had a postvaccination serology result, and followed the protocol procedures. Serotype 9V is one of 7 individual serotypes contained in Prevnar™.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: VAQTA™ + ProQuad™ + Prevnar™</title>
            <description>VAQTA™ (hepatitis A vaccine) + ProQuad™ (measles, mumps, rubella, and varicella vaccine) + Prevnar™ (pneumococcal 7-valent conjugate vaccine) administered at the same time at first study visit. Second doses of VAQTA™ and ProQuad™ administered together 24 weeks later at third study visit.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: VAQTA™ Separate From ProQuad™ and Prevnar™</title>
            <description>VAQTA™ (hepatitis A vaccine) dose 1 administered separately from ProQuad™ (measles, mumps, rubella, and varicella vaccine) and Prevnar™ (pneumococcal 7-valent conjugate vaccine). A second dose of VAQTA™ administered 24 weeks after the first dose at third study visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Response to S. Pneumoniae Serotype 9V - Participants With a Serological Response</title>
          <description>Number of participants with a postvaccination titer &gt;=0.2 mcg/mL for S. pneumoniae serotype 9V</description>
          <population>Per-protocol analysis set includes participants who received Prevnar™ (pneumococcal 7-valent conjugate vaccine), had a postvaccination serology result, and followed the protocol procedures. Serotype 9V is one of 7 individual serotypes contained in Prevnar™.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="247"/>
                <count group_id="O2" value="247"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="243"/>
                    <measurement group_id="O2" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Antibody Response to S. Pneumoniae Serotype 14 - Participants With a Serological Response</title>
        <description>Number of participants with a postvaccination titer &gt;=0.2 mcg/mL for S. pneumoniae serotype 14</description>
        <time_frame>6 weeks postvaccination of pneumococcal 7-valent conjugate vaccine (Prevnar™)</time_frame>
        <population>Per-protocol analysis set includes participants who received Prevnar™ (pneumococcal 7-valent conjugate vaccine), had a postvaccination serology result, and followed the protocol procedures. Serotype 14 is one of 7 individual serotypes contained in Prevnar™.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: VAQTA™ + ProQuad™ + Prevnar™</title>
            <description>VAQTA™ (hepatitis A vaccine) + ProQuad™ (measles, mumps, rubella, and varicella vaccine) + Prevnar™ (pneumococcal 7-valent conjugate vaccine) administered at the same time at first study visit. Second doses of VAQTA™ and ProQuad™ administered together 24 weeks later at third study visit.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: VAQTA™ Separate From ProQuad™ and Prevnar™</title>
            <description>VAQTA™ (hepatitis A vaccine) dose 1 administered separately from ProQuad™ (measles, mumps, rubella, and varicella vaccine) and Prevnar™ (pneumococcal 7-valent conjugate vaccine). A second dose of VAQTA™ administered 24 weeks after the first dose at third study visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Response to S. Pneumoniae Serotype 14 - Participants With a Serological Response</title>
          <description>Number of participants with a postvaccination titer &gt;=0.2 mcg/mL for S. pneumoniae serotype 14</description>
          <population>Per-protocol analysis set includes participants who received Prevnar™ (pneumococcal 7-valent conjugate vaccine), had a postvaccination serology result, and followed the protocol procedures. Serotype 14 is one of 7 individual serotypes contained in Prevnar™.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="248"/>
                <count group_id="O2" value="247"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245"/>
                    <measurement group_id="O2" value="244"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Antibody Response to S. Pneumoniae Serotype 18C - Participants With a Serological Response</title>
        <description>Number of participants with a postvaccination titer &gt;=0.2 mcg/mL for S. pneumoniae serotype 18C</description>
        <time_frame>6 weeks postvaccination of pneumococcal 7-valent conjugate vaccine (Prevnar™)</time_frame>
        <population>Per-protocol analysis set includes participants who received Prevnar™ (pneumococcal 7-valent conjugate vaccine), had a postvaccination serology result, and followed the protocol procedures. Serotype 18C is one of 7 individual serotypes contained in Prevnar™.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: VAQTA™ + ProQuad™ + Prevnar™</title>
            <description>VAQTA™ (hepatitis A vaccine) + ProQuad™ (measles, mumps, rubella, and varicella vaccine) + Prevnar™ (pneumococcal 7-valent conjugate vaccine) administered at the same time at first study visit. Second doses of VAQTA™ and ProQuad™ administered together 24 weeks later at third study visit.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: VAQTA™ Separate From ProQuad™ and Prevnar™</title>
            <description>VAQTA™ (hepatitis A vaccine) dose 1 administered separately from ProQuad™ (measles, mumps, rubella, and varicella vaccine) and Prevnar™ (pneumococcal 7-valent conjugate vaccine). A second dose of VAQTA™ administered 24 weeks after the first dose at third study visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Response to S. Pneumoniae Serotype 18C - Participants With a Serological Response</title>
          <description>Number of participants with a postvaccination titer &gt;=0.2 mcg/mL for S. pneumoniae serotype 18C</description>
          <population>Per-protocol analysis set includes participants who received Prevnar™ (pneumococcal 7-valent conjugate vaccine), had a postvaccination serology result, and followed the protocol procedures. Serotype 18C is one of 7 individual serotypes contained in Prevnar™.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="247"/>
                <count group_id="O2" value="247"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245"/>
                    <measurement group_id="O2" value="243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Antibody Response to S. Pneumoniae Serotype 19F - Participants With a Serological Response</title>
        <description>Number of participants with a postvaccination titer &gt;=0.2 mcg/mL for S. pneumoniae serotype 19F</description>
        <time_frame>6 weeks postvaccination of pneumococcal 7-valent conjugate vaccine (Prevnar™)</time_frame>
        <population>Per-protocol analysis set includes participants who received Prevnar™ (pneumococcal 7-valent conjugate vaccine), had a postvaccination serology result, and followed the protocol procedures. Serotype 19F is one of 7 individual serotypes contained in Prevnar™.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: VAQTA™ + ProQuad™ + Prevnar™</title>
            <description>VAQTA™ (hepatitis A vaccine) + ProQuad™ (measles, mumps, rubella, and varicella vaccine) + Prevnar™ (pneumococcal 7-valent conjugate vaccine) administered at the same time at first study visit. Second doses of VAQTA™ and ProQuad™ administered together 24 weeks later at third study visit.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: VAQTA™ Separate From ProQuad™ and Prevnar™</title>
            <description>VAQTA™ (hepatitis A vaccine) dose 1 administered separately from ProQuad™ (measles, mumps, rubella, and varicella vaccine) and Prevnar™ (pneumococcal 7-valent conjugate vaccine). A second dose of VAQTA™ administered 24 weeks after the first dose at third study visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Response to S. Pneumoniae Serotype 19F - Participants With a Serological Response</title>
          <description>Number of participants with a postvaccination titer &gt;=0.2 mcg/mL for S. pneumoniae serotype 19F</description>
          <population>Per-protocol analysis set includes participants who received Prevnar™ (pneumococcal 7-valent conjugate vaccine), had a postvaccination serology result, and followed the protocol procedures. Serotype 19F is one of 7 individual serotypes contained in Prevnar™.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="248"/>
                <count group_id="O2" value="248"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245"/>
                    <measurement group_id="O2" value="244"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Antibody Response to S. Pneumoniae Serotype 23F - Participants With a Serological Response</title>
        <description>Number of participants with a postvaccination titer &gt;=0.2 mcg/mL for S. pneumoniae serotype 23F</description>
        <time_frame>6 weeks postvaccination of pneumococcal 7-valent conjugate vaccine (Prevnar™)</time_frame>
        <population>Per-protocol analysis set includes participants who received Prevnar™ (pneumococcal 7-valent conjugate vaccine), had a postvaccination serology result, and followed the protocol procedures. Serotype 23F is one of 7 individual serotypes contained in Prevnar™.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: VAQTA™ + ProQuad™ + Prevnar™</title>
            <description>VAQTA™ (hepatitis A vaccine) + ProQuad™ (measles, mumps, rubella, and varicella vaccine) + Prevnar™ (pneumococcal 7-valent conjugate vaccine) administered at the same time at first study visit. Second doses of VAQTA™ and ProQuad™ administered together 24 weeks later at third study visit.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: VAQTA™ Separate From ProQuad™ and Prevnar™</title>
            <description>VAQTA™ (hepatitis A vaccine) dose 1 administered separately from ProQuad™ (measles, mumps, rubella, and varicella vaccine) and Prevnar™ (pneumococcal 7-valent conjugate vaccine). A second dose of VAQTA™ administered 24 weeks after the first dose at third study visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Response to S. Pneumoniae Serotype 23F - Participants With a Serological Response</title>
          <description>Number of participants with a postvaccination titer &gt;=0.2 mcg/mL for S. pneumoniae serotype 23F</description>
          <population>Per-protocol analysis set includes participants who received Prevnar™ (pneumococcal 7-valent conjugate vaccine), had a postvaccination serology result, and followed the protocol procedures. Serotype 23F is one of 7 individual serotypes contained in Prevnar™.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="247"/>
                <count group_id="O2" value="247"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245"/>
                    <measurement group_id="O2" value="246"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Arm 1: VAQTA™ + ProQuad™ + Prevnar™</title>
          <description>VAQTA™ (hepatitis A vaccine) + ProQuad™ (measles, mumps, rubella, and varicella vaccine) + Prevnar™ (pneumococcal 7-valent conjugate vaccine) administered at the same time at first study visit. Second doses of VAQTA™ and ProQuad™ administered together 24 weeks later at third study visit.</description>
        </group>
        <group group_id="E2">
          <title>Arm 2: VAQTA™ Separate From ProQuad™ and Prevnar™</title>
          <description>VAQTA™ (hepatitis A vaccine) dose 1 administered separately from ProQuad™ (measles, mumps, rubella, and varicella vaccine) and Prevnar™ (pneumococcal 7-valent conjugate vaccine). A second dose of VAQTA™ administered 24 weeks after the first dose at third study visit.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2"/>
                <counts group_id="E2" subjects_affected="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="323"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="323"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="323"/>
              </event>
              <event>
                <sub_title>Perineal Abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="323"/>
              </event>
              <event>
                <sub_title>Genital Abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="323"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="323"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="323"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="323"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile Convulsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="323"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="231"/>
                <counts group_id="E2" subjects_affected="172"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="286"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Otorrhea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="286"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Eye Discharge</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Eye Swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="286"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Gastroesophageal Reflux Disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Oral Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Teething</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="286"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Body Temperature</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="126" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Bruising, Injection site for VAQTA™</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Erythema, Injection site for VAQTA™</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Haemorrhage, Injection site for VAQTA™</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Nodule, Injection site for VAQTA™</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Pain, Injection site for VAQTA™</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="86" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="73" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Rash, Injection site for VAQTA™</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Reaction, Injection site for VAQTA™</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Swelling, Injection site for VAQTA™</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Warmth, Injection site for VAQTA™</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="286"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Multiple Allergies</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Seasonal Allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="286"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Adenovirus Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Body Tinea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Candida Nappy Rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Conjunctivitis Bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Conjunctivitis Infective</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Conjunctivitis Viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Croup Infectious</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Ear Infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Enterobiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Eye Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Gastroenteritis Viral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Impetigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Mycoplasma Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Otitis Media</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Otitis Media Acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Pharyngitis Streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Respiratory Syncytial Virus Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Roseola</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Skin Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Tinea Pedis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Viraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Viral Infection</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Viral Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Viral Skin Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="286"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod Bite</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Arthropod Sting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Head Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Lower Limb Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Sunburn</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Thermal Burn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="286"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Hypervitaminosis A</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Iron Deficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="286"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscular Weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Pain In Extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="286"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="286"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Crying</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Sleep Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="286"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Penile Discharge</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="286"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Bronchial Hyperreactivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Nasal Congestion</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Paranasal Sinus Hypersecretion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Congestion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Rhinalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Rhinitis Allergic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Rhinorrhea</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Sinus Congestion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Sneezing</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="286"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Dermatitis Allergic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Dermatitis Atopic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Dermatitis Contact</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Dermatitis Diaper</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Erythema Multiforme</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Rash Macular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Rash Maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Rash Morbilliform</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Rash Rubelliform</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Rash Vesicular</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="286"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

